Antivirals present ‘Pandora’s box’ of potential drug interactions

Hospital pharmacists warn of the need to support safe prescribing and dispensing of incoming novel oral COVID-19 treatments Leading hospital pharmacists are calling for a “consistent and streamlined” approach to support the safe prescribing and dispensing of novel oral COVID-19 treatments, with supplies of nirmatrelvir/ritonavir (Paxlovid) and molnupiravir (Lagevrio) due for imminent use in Australia.

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous ‘We make no apology for putting patients first.’
Next The top ten